Page last updated: 2024-11-04

vorinostat and Agnogenic Myeloid Metaplasia

vorinostat has been researched along with Agnogenic Myeloid Metaplasia in 3 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Research Excerpts

ExcerptRelevanceReference
"Because primary myelofibrosis (PMF) originates at the level of the pluripotent hematopoietic stem cell (HSC), we examined the effects of various therapeutic agents on the in vitro and in vivo behavior of PMF CD34(+) cells."1.36Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells. ( Hoffman, R; Li, Y; Lu, M; Najfeld, V; Tripodi, J; Wang, X; Xu, M; Zhang, W, 2010)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andersen, CL1
Mortensen, NB1
Klausen, TW1
Vestergaard, H1
Bjerrum, OW1
Hasselbalch, HC1
Lee, J1
Wang, X1
Zhang, W1
Tripodi, J1
Lu, M1
Xu, M1
Najfeld, V1
Li, Y1
Hoffman, R1

Trials

1 trial available for vorinostat and Agnogenic Myeloid Metaplasia

ArticleYear
A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis.
    Haematologica, 2014, Volume: 99, Issue:1

    Topics: Humans; Hydroxamic Acids; Polycythemia Vera; Primary Myelofibrosis; Treatment Outcome; Vorinostat

2014

Other Studies

2 other studies available for vorinostat and Agnogenic Myeloid Metaplasia

ArticleYear
Clinical efficacy of vorinostat in a patient with essential thrombocytosis and subsequent myelofibrosis.
    Annals of hematology, 2009, Volume: 88, Issue:7

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Blood Transfusion; Humans; Hyd

2009
Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells.
    Blood, 2010, Dec-23, Volume: 116, Issue:26

    Topics: Animals; Antigens, CD34; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Bone M

2010